Vical Inc. and Astellas Pharma Inc. began a Phase III trial of Transvax, a vaccine for cytomeglovirus (CMV), in 500 hematopoietic cell transplant recipients, with Astellas taking the lead and Vical providing development, regulatory and manufacturing support.